Innovations involving augmented co-factors, combining antitumor agents and super inhibitors, such as THZ1 and JQ1 (direct MYC inhibitors) with self-immune response, to modulate multiple signaling pathways simultaneously, may prevent cancer recurrence and progression to MDR in the long-term [587]. Here, MYC is linked to cancer.